Interviews

Amaia Lujambio Goizueta, PhD, discusses mutations commonly seen in hepatocellular carcinoma, and the targeted therapies available for these tumors.

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.

Nizar M. Tannir, MD, FACP, discusses why telaglenastat in combination with cabozantinib did not improve efficacy in compared with cabozantinib alone in patients with metastatic renal cell carcinoma.

Christopher R. Flowers, MD, discusses the current therapies used for patients with relapsed/refractory diffuse large B-cell lymphoma and goes into specifics of the L-MIND trial after the long-term follow-up.

Thomas G. Martin, MD, discusses the use of anti-CD38 antibodies in patients with multiple myeloma.

Othman Al-Sawaf, MD, discusses the use of venetoclax plus obinutuzumab in patients with untreated chronic lymphocytic leukemia on the CLL14 study.

Dennis J. Slamon, MD, PhD, discusses the subgroup benefits and safety profile of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Bijal Shah, MD, MS, discusses the results of treatment with the chimeric antigen receptor T-cell therapy brexucabtagne autoleucel in the ZUMA-3 trial in patients with acute lymphoblastic leukemia.

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.

Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.

Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.

Larry D. Anderson, Jr, MD, PhD, discusses the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Mehrdad Abedi, MD, discusses Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.

In an interview with Targeted Oncology, David W. Dougherty, MD, discussed how the COVID-19 pandemic has changed the cancer care space.

Bijal Shah, MD, MS, discusses the timing of treatment with chimeric antigen receptor T-cell therapy in regard to the data from the ZUMA-3 trial of brexucabtagne autoleucel in patients with acute lymphoblastic leukemia.

Brian I. Rini, MD, discusses the benefits of long-term follow-up for trials and the results from 42-month follow-up of the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line therapy for patients with advanced clear cell renal cell carcinoma.

Maurie Markman, MD, addresses different treatment options, including checkpoint inhibitors, for patients with endometrial cancer.

Mounzer Agha, MD, discusses the phase 2 CARTITUDE-2 trial looking at ciltacabtagene autoleucel in patients with multiple myeloma.

Jyoti Malhotra, MD, MPH, discusses the preliminary efficacy signals of the combination therapy plinabulin, nivolumab, and ipilimumab in patients with relapsed/refractory small cell lung cancer.

Paul K. Paik, MD, discusses the newest data from the VISION trial of tepotinib in patients with non–small cell lung cancer and a MET exon 14 skipping mutations.

Debu Tripathy, MD, discusses the TBCRC049 study investigating the use of tucatinib, capecitabine, and trastuzumab in the cerebral spinal fluid of patients with HER2-positive breast cancer and leptomeningeal disease.

Jan Philipp Bewersdorf, MD, discusses the safety outcomes of a systematic review and meta-analysis of 43 studies investigating efficacy and safety of allogeneic hematopoietic cell transplant in 8739 patients with primary or secondary myelofibrosis.

Peter Riedell, MD, discusses the effect of time to relapse in patients with mantle cell lymphoma after frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation.

Efstathios Kastritis, MD, discusses the amyloidosis setting, current standards of care, and the phase 3 ANDROMEDA trial.

Amit Singal, MD, discusses options after surgical resection for patients with hepatocellular carcinoma.

Michael Bishop, MD, discusses the different settings where chimeric antigen receptor T-cell therapy are used.

Thomas Bachelot, MD, PhD, discusses therapies available for patients with HER2-positive breast cancer and brain metastases.

Mitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.

Michael Bishop, MD, discusses the investigations of and responses to chimeric antigen receptor T-cell therapy in different disease types.

Jorge E. Cortes, MD, discusses the 5-year overall survival results of CPX-351 versus 7+3 in patients with newly diagnosed high-risk or secondary acute myeloid leukemia.